Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q1 2025 Earnings Presentation
15 slides from Vitrolife Ab's earnings presentation, Apr 24, 2025
Slide 1: First Quarter 2025
FIRST QUARTER 2025 Bronwyn Brophy O’Connor, CEO Helena Wennerström, Acting CFO Vitrolife AB (publ) 2025-04-24
Slide 2: Q1/2025 Highlights
Q1 /2025 Highlights Q1 /2025 Highlights Growth EMEA Americas Strengthened +1%* +14%* +9%* +9%** organizational organisational structure * Organic growth in local currencies excluding discontinued business 2 **Organic growth in local currencies
Slide 3: Strong performance in EMEA
Strong performance in EMEA First quarter 2025 Sales Organic growth in local currencies Gross margin excluding discontinued business 842 MSEK +3% 57.4% (841 MSEK) 0% in SEK +1% in local currencies (57.1%) EBITDA Operating cash flow Earnings per share 257 MSEK 69 MSEK 0.74 SEK Margin 30.6% (32.4%) (198
Slide 4: Sales and growth per geographical segment
Sales and growth per geographical segment Americas EMEA APAC Total Organic growth* +9% +8% -15% +1% excluding discontinued +9% +14% -15% +3% business* Sales (MSEK) 270 334 238 842 Share of total sales 32% 40% 28% 4 * Organic growth in local currencies
Slide 5: Market region EMEA
Market region EMEA Net sales, MSEK +8% 383 Organic growth* 345 355 334 +8% 328 313 311 310 +14%* excluding discontinued business • Strong sales across the entire Consumables portfolio. • Record quarter for Technologies sales in the region with the highest penetration of time-lapse • Weaker performan
Slide 6: Market region Americas
Market region Americas Net sales, MSEK 316 +9% 311 Organic growth* 298 285 287 273 +9% 270 248 • Steady growth in Consumables in North America however soft quarter in LATAM impacting result. • Technologies performing well as we continue to drive penetration of EmbryoScope®. • Genetics performed very
Slide 7: Market region APAC
Market region APAC Net sales, MSEK 294 -15% Organic growth* 283 272 270 266 265 -15% 252 238 • Consumables and Technologies significantly impacted by the Year of the Dragon with strong comparable revenue. • Q1 2024 was also an exceptionally strong quarter for Technologies with a record number of Embr
Slide 8: Revenue per segment and product group Q1 2025
Revenue per segment and product group Q1 2025 Consumables APAC 41% 28% Americas 32% Genetics 41% Revenue by Revenue by geography product groups EMEA Technologies 40% 18% Good geographic balance has proved critical in Well balanced from a product group perspective. the changing macroeconomic enviro
Slide 9: Geographical segments
Geographical segments Americas EMEA APAC Total Sales (MSEK) 270 334 238 842 Gross income (MSEK) 145 199 139 483 Gross margin % 53.7% 59,6% 58.4% 57.4% Selling expenses (MSEK) -77 -68 -38 -183 Market contribution (MSEK) 68 131 101 300 Contribution margin % 25.3% 39.2% 42.4% 35.6% Contribution margin
Slide 10: Q1 financial highlights
Q1 financial highlights MSEK 841 842 0% Net sales of SEK 842 million (841), +0% in SEK • Organic growth in local currencies +1% 481 483 • Currency effect -1% • Organic growth in local currencies excluding discontinued business +3%. 272 257 Gross income of SEK 483 million (481) • Margin of 57.4% (57.1
Slide 11: Operating expenses
Operating expenses MSEK +6% 333 313 Operating expenses • Continue to invest in Sales and Marketing capabilities in key markets 169 183 • R&D expenses have decreased mainly due to a reduction in expenses for external services and a slight increase in capitalisation. • Other operating expenses increas
Slide 12: Key financials
Key financials MSEK* 2025 Q1 2024 Q1 Sales 842 841 Gross Margin, % 57.4 57.1 EBITDA 257 272 EBITDA Margin, % 30.6 32.4 Net income 100 115 EPS, SEK 0.74 0.85 Operating cash flow 69 198 Net Debt / EBITDA rolling 12m 0.6 0.9 12 *Unless otherwise indicated.
Slide 13: Focus for 2025
Focus for 2025 1. Continue to drive share gain in key markets leveraging the full breadth of the portfolio. 2. Accelerate penetration of our combined EmbryoScope and lab control solutions. Growth 3. Deliver best in class quality and customer service to further differentiate from competitors. 1. Prio
Slide 14: Q&A
Q&A Contact: Helena Wennerström, acting CFO, investors@vitrolife.com
Slide 15: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there